Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBITDA Margin (2019 - 2025)

Pulmonx has reported EBITDA Margin over the past 7 years, most recently at 66.76% for Q3 2025.

  • Quarterly EBITDA Margin fell 14.0% to 66.76% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 62.24% through Sep 2025, up 903.0% year-over-year, with the annual reading at 67.93% for FY2024, 1911.0% up from the prior year.
  • EBITDA Margin was 66.76% for Q3 2025 at Pulmonx, down from 61.78% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 57.21% in Q4 2024 and troughed at 149.25% in Q1 2022.
  • The 5-year median for EBITDA Margin is 84.4% (2023), against an average of 88.67%.
  • The largest YoY upside for EBITDA Margin was 21958bps in 2021 against a maximum downside of -5843bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 93.65% in 2021, then rose by 2bps to 91.44% in 2022, then grew by 25bps to 68.43% in 2023, then increased by 16bps to 57.21% in 2024, then fell by -17bps to 66.76% in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBITDA Margin are 66.76% (Q3 2025), 61.78% (Q2 2025), and 63.71% (Q1 2025).